Holen Sie sich die Stockscreener-App
325.03
0.36%
1.18
Handel nachbörslich:
321.64
-3.39
-1.04%
Schlusskurs vom Vortag:
$323.85
Offen:
$324.22
24-Stunden-Volumen:
960.66K
Relative Volume:
1.11
Marktkapitalisierung:
$22.88B
Einnahmen:
$2.20B
Nettoeinkommen (Verlust:
$402.20M
KGV:
58.46
EPS:
5.56
Netto-Cashflow:
$280.80M
1W Leistung:
+1.14%
1M Leistung:
+29.35%
6M Leistung:
+21.83%
1J Leistung:
+84.73%
1-Tages-Spanne:
$320.71
$326.24
1-Wochen-Bereich:
$320.71
$329.10
52-Wochen-Spanne:
$172.07
$329.33
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Vergleichen Sie PODD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
325.03 | 22.62B | 2.20B | 402.20M | 280.80M | 5.56 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Goldman Sachs Initiates Coverage on Insulet (PODD) with Buy Rati - GuruFocus
Goldman Sachs Initiates Coverage on Insulet (PODD) with a Buy Ra - GuruFocus
Goldman Sachs initiates coverage of medtech stocks Insulet and Dexcom at Buy - Investing.com
Goldman Sachs Initiates Insulet at Buy With $380 Price Target - marketscreener.com
Goldman Sachs starts Insulet stock with buy, $380 target - Investing.com
Goldman Sachs Starts Insulet Corporation (PODD) at Buy - StreetInsider
Goldman Sachs Initiates Coverage on Insulet (PODD) with Positive Outlook | PODD Stock News - GuruFocus
Insulet initiated with a Buy at Goldman Sachs - TipRanks
Questions About High-Flying Insulet Corp. - Law Street Media
Insulet Corporation (PODD) Announces Approval of 2025 Stock Opti - GuruFocus
Insulet Corporation: Shares Remain Astronomically Expensive (NASDAQ:PODD) - Seeking Alpha
Insulet Corporation Holds 2025 Annual Stockholders Meeting - TipRanks
Is Insulet Corporation (NASDAQ:PODD) A High Quality Stock To Own? - Yahoo Finance
What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing? - simplywall.st
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today - Benzinga
Raymond James Increases Price Target for Insulet (PODD) to $360 - GuruFocus
Insulet Gains 78.5% in a Year: What's Driving the Stock? - MSN
Insulet (PODD) Target Price Raised by Raymond James | PODD Stock News - GuruFocus
Raymond James Increases Price Target for Insulet (PODD) to $360 | PODD Stock News - GuruFocus
Raymond James Adjusts Price Target on Insulet to $360 From $328, Maintains Outperform Rating - marketscreener.com
Insulet stock target lifted to $360 by Raymond James - Investing.com India
Insulet Corporation (PODD) PT Raised to $360 at Raymond James - StreetInsider
(PODD) Technical Data - news.stocktradersdaily.com
Insulet Foe Rips $30M Atty Fee Ask As 'Over-Lawyered' - Law360
Insulet to Present at the Goldman Sachs 46th Annual Global Healt - GuruFocus
Do Wall Street Analysts Like Insulet Stock? - MSN
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - Eagle-Tribune
Analysts Turn Bullish on Insulet Stock (PODD) after Strong Q1 Earnings - MSN
5 Analysts Assess Insulet: What You Need To KnowInsulet (NASDAQ:PODD) - Benzinga
Insulet (PODD) Price Target Raised by Citigroup to $380 | PODD Stock News - GuruFocus
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
Citigroup Adjusts Price Target on Insulet to $380 From $320, Maintains Buy Rating - marketscreener.com
Citi adds Edwards Lifesciences stock as Top Pick, drops Insulet - Investing.com
Global Insulin Pumps Market Report 2021-2030: Insulet, - openPR.com
Insulet stock soars to 52-week high, reaches $326.53 By Investing.com - Investing.com South Africa
Insulet stock soars to 52-week high, reaches $326.53 - Investing.com
Captrust Financial Advisors Raises Stake in Insulet Co. (NASDAQ:PODD) - Defense World
Here's What to Expect From Insulet's Next Earnings Report - MSN
Insulet Adds Stryker Executive to Board - Medical Product Outsourcing
Insulet Creates Medical Director Position - Medical Product Outsourcing
Insulet stock price target raised to $375 by Bernstein - Investing.com Australia
'Insulet Corporation (PODD) is Our Top Pick in Diabetes'; PT Raised to $375 at Bernstein - StreetInsider
Here's Why Insulet (PODD) is a Strong Momentum Stock - Yahoo Finance
Bernstein Boosts Insulet (PODD) Price Target Amid Strong Market Position | PODD Stock News - GuruFocus
Insulet’s SVP Cashes In: A Multi-Million Dollar Stock Sale! - TipRanks
Insulet (PODD) – Investment Analysts’ Weekly Ratings Changes - Defense World
Insulet Names New CEO, Expects to Top Revenue Projections - MSN
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer - MSN
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - Yahoo Finance
Bernstein Adjusts Insulet Price Target to $375 From $355 - marketscreener.com
Subdued Growth No Barrier To Insulet Corporation (NASDAQ:PODD) With Shares Advancing 26% - simplywall.st
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.09%
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):